Technology Appraisal Guidance No. 430
Source: National Institute for Health and Care Excellence
1.1 Sofosbuvir–velpatasvir is recommended as an option for treating chronic hepatitis C in adults, as specified in table 1, only if the company provides the drug with the discount agreed in the simple discount agreement.
Table 1 Sofosbuvir-velpatasvir for treating chronic hepatitis C in adults
|Liver disease stage||Treatment||Recommendation according to treatment history|
|1||With or without compensated cirrhosis||Sofosbuvir-velpatasvir||Recommended|
|2||Without cirrhosis||Sofosbuvir-velpatasvir||Recommended only for people who cannot tolerate interferon or it is not suitable for them||Recommended|
|Compensated cirrhosis||Sofosbuvir-velpatasvir (with or without ribavirin)||Recommended|
|4||With or without compensated cirrhosis||Sofosbuvir-velpatasvir||Recommended|
|5||With or without compensated cirrhosis||Sofosbuvir-velpatasvir||Recommended|
|6||With or without compensated cirrhosis||Sofosbuvir-velpatasvir||Recommended|
|1-6||Decompensated cirrhosis||Sofosbuvir-velpatasvir (with ribavirin)||Recommended|
|Abbreviation: HCV, hepatitis C virus
Treated - the person's hepatitis C has not adequately responded to interferon-based treatment.
1.2 It is recommended that the decision to treat and prescribing decisions are made by multidisciplinary teams in the operational delivery networks put in place by NHS England, to prioritise treatment for people with the highest unmet clinical need.
1.3 This guidance is not intended to affect the position of patients whose treatment with sofosbuvir–velpatasvir was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.
The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at www.nice.org.uk/guidance/ta430
This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: firstname.lastname@example.org
Sofosbuvir-velpatasvir for treating chronic hepatitis C
Issue Date: January 2017